Antithrombotic Treatment of Stable Coronary Artery Disease

被引：4

作者：

Li, Yi-Heng ^{[1
]}

Hsieh, I-Chang ^{[2
]}

Ueng, Kwo-Chang ^{[3
]}

Wang, Yu-Chen ^{[4
,5
]}

Cheng, Shu-Meng ^{[6
]}

Wu, Cho-Kai ^{[7
,8
]}

Wu, Chiung-Jen ^{[9
,10
]}

Hsieh, Ming-Hsiung ^{[11
,12
]}

Jen, Hsu-Lung ^{[13
]}

Chang, Chi-Jen ^{[2
]}

Chen, Ying-Hwa ^{[14
,15
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Tainan, Taiwan

[2] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Taoyuan, Taiwan

[3] Chung Shan Med Univ Hosp, Taichung, Taiwan

[4] Asia Univ, Asia Univ Hosp, Taichung, Taiwan

[5] China Med Univ, Coll Med & Hosp, Taichung, Taiwan

[6] Triserv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan

[7] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[10] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[11] Taipei Med Univ, Taipei, Taiwan

[12] Taipei Wan Fang Hosp, Taipei, Taiwan

[13] Cheng Hsin Gen Hosp, Taipei, Taiwan

[14] Taipei Vet Gen Hosp, Taipei, Taiwan

[15] Natl Yang Ming Chiao Tung Univ, Taipei, Taiwan

来源：

ACTA CARDIOLOGICA SINICA | 2021年 / 37卷 / 06期

关键词：

Antithrombotics; Coronary artery disease; Dual antiplatelet therapy; Dual pathway inhibition; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; FOCUSED UPDATE; ESC GUIDELINES; MANAGEMENT; ASPIRIN; RISK; RIVAROXABAN; DETERMINANTS; VALIDATION;

D O I：

10.6515/ACS.202111_37(6).20210513A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronary artery disease (CAD) is one of the leading causes of death in Taiwan. Despite the use of current guideline-recommended therapies for secondary prevention, the residual risk of recurrent cardiovascular events remains high in CAD, warranting the need for new treatment options. Antithrombotic drugs are one of the most important medical therapies for CAD. In this article, we review the unmet needs of the current antithrombotic agents and summarize the results of clinical trials with dual antiplatelet therapy in stable CAD. We also review data from a recent study demonstrating the benefits of a dual pathway inhibition strategy with antiplatelet and anticoagulant therapy, a new option for CAD treatment. Finally, we propose a treatment algorithm for choosing different antithrombotic regimens for CAD based on current scientific evidence and expert opinions.

引用

页码：574 / 579

页数：6

共 50 条

[41] New antithrombotic drugs in coronary artery disease.
Montalescot, G
REVUE DE MEDECINE INTERNE, 1997, 18 (06): : 450 - 459
[42] Current Antithrombotic Therapy: Beyond Coronary Artery Disease
Mystakidi, Vasiliki-Chara
Oikonomou, Evangelos
Tousoulis, Dimitris
CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (23) : 2683 - 2685
[43] Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease
Becker, Richard C.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12): : 1169 - 1170
[44] OPTIMAL ANTITHROMBOTIC THERAPY FOR ATRIAL FIBRILLATION AND STABLE CORONARY ARTERY DISEASE - A NETWORK META-ANALYSIS
Gupta, Rahul
Malik, Aaqib
Biggs, Ross
Vadhar, Sagar
Racharla, Lekha
Nagahama, Makoto
Vyas, Apurva
Patel, Nainesh
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 153 - 153
[45] Antithrombotic monotherapy for stable coronary artery disease and atrial fibrillation patients with and without prior coronary artery revascularization: Insights from the AFIRE trial
Noda, T.
Nochioka, K.
Kaikita, K.
Akao, M.
Ako, J.
Matoba, T.
Nakamura, M.
Miyauchi, K.
Hagiwara, N.
Kimura, K.
Hirayama, A.
Matsui, K.
Ogawa, H.
Yasuda, S.
EUROPEAN HEART JOURNAL, 2023, 44 : 62 - 63
[46] Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy "REGATTA" results)
Shakhmatova, O. O.
Komarov, A. L.
Korobkova, V. V.
Yarovaya, E. B.
Andreevskaya, M., V
Shuleshova, A. G.
Panchenko, E. P.
TERAPEVTICHESKII ARKHIV, 2020, 92 (09) : 30 - 38
[47] Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial
Noda, Takashi
Nochioka, Kotaro
Kaikita, Koichi
Akao, Masaharu
Ako, Junya
Matoba, Tetsuya
Nakamura, Masato
Miyauchi, Katsumi
Hagiwara, Nobuhisa
Kimura, Kazuo
Hirayama, Atsushi
Matsui, Kunihiko
Ogawa, Hisao
Yasuda, Satoshi
EUROINTERVENTION, 2024, 20 (07) : E425 - E435
[48] Antithrombotic Treatment for Symptomatic Peripheral Artery Disease
Li, Yi-Heng
Yeh, Hung-I
Hwang, Juey-Jen
ACTA CARDIOLOGICA SINICA, 2019, 35 (06) : 557 - 562
[49] Antithrombotic treatment in stable coronary syndromes: Long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris
Schoebel, FC
Jax, TW
Fischer, Y
Strauer, BE
Leschke, M
HEART, 1997, 77 (01) : 13 - 17
[50] HYPERTENSION AND STABLE CORONARY ARTERY DISEASE
Pedrinelli, R.
CARDIOLOGY, 2015, 132 : 94 - 94

← 1 2 3 4 5 →